Physician profile
Arooge Towheed
NPI 1588071930
$60,098.58
in general payments reported to CMS, 2019-2025
20 companies · $1,068 in 2025
The $1,068 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.66 · 2020: $34K · 2021: $11K · 2022: $3,039 · 2023: $8,512 · 2024: $2,676 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,058 · Food and Beverage: $4,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,057.95 |
| Food and Beverage | $4,198.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $25,000.00 | 2020 | |
| Medtronic, INC. | $16,907.57 | 2021-2025 | Evera Mri Xt Dr Surescan, Micra, Azure Xt Dr Mri Surescan |
| Abbott Laboratories | $13,906.96 | 2020-2025 | Aveir |
| Philips North America LLC | $1,297.76 | 2022 | |
| Boston Scientific Corporation | $984.35 | 2019-2025 | Watchman Access System, Watchman Flx, Farapulse |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $513.26 | 2022-2025 | Lifevest |
| Biotronik INC. | $351.33 | 2022-2025 | Amvia Edge, Acticor 7 Vr-T Dx, Pamira |
| Biosense Webster, INC. | $248.97 | 2022-2025 | Carto 3, Smartablate |
| Medical Device Business Services, INC. | $174.27 | 2023 | Carto 3 |
| Novartis Pharmaceuticals Corporation | $150.91 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.67 | 2022-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $88.39 | 2025 | Wegovy |
| Kestra Medical Technology Services, INC. | $66.31 | 2023-2025 | Assure Wcd |
| Atricure, INC. | $64.48 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $51.91 | 2022-2025 | Farxiga, Brilinta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $45.83 | 2025 | Kengreal |
| Pfizer INC. | $45.38 | 2025 | |
| Cvrx, INC. | $31.63 | 2024 | Barostim Neo System |
| Cardiva Medical, INC. | $23.73 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Cordis US Corp. | $19.87 | 2025 | Mynx Control Venous |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arooge Towheed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.